Baseline kidney function testing before initiating either substance, with periodic monitoring based on individual risk factors, represents prudent clinical practice, particularly in patients with diabetes or other kidney disease risk factors
In research, GH secretagogues are usually grouped into two major categories: GHRH analogs, which activate the growth hormonereleasing hormone receptor Ghrelin/GHSR agonists, which activate the growth hormone secretagogue receptor Both pathways can increase GH-axis activity, but they do so through different upstream signals
According to some early users, they mentioned satisfaction from consistent use rather than immediate dramatic effects
R., Audhya, T., & Geier, M
Presented for research literature review only Dale O et al